Algunas páginas están disponibles en Español.
Download PDF
Medical Innovations for Neglected Patients
Fatal Imbalance: The Crisis in Research and Development for Drugs for Neglected Diseases
Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 2002;359(9324):2188–2194.
Moon S, Bermudez J, t’Hoen E, Innovation and Access to Medicines for Neglected Populations: Could a Treaty Address a Broken Pharmaceutical R&D System?, PLoS Medicine 2012; 9(5):e1001218.
Moon S, Szlezak NA, Michaud CM, Jamison DT, Keusch GT, Clark WC, Bloom BR, The Global Health Systems: Lessons for a Stronger Institutional Framework, PLoS Medicine 2010; 7(1): e1000193.
Rottingen JA, Moon S, Tangcharoensathien V, Hoffman SJ, “Multi-stakeholder Technical Meeting on Implementations Options Recommended by the WHO Consultative Expert Working Group on Research & Development (CEWG): Financing and Coordination.” Report of this meeting at the Rockefeller Foundation Bellagio Center in New York, New York on October 16-19, 2012
Overview
Chaisson RE, Nuermberger EL, Confronting Multidrug-Resistant Tuberculosis, The New England Journal of Medicine 2012: 366(23): 2223-2224.
Zumla A, Abubakar I, Raviglione, Hoeschler M, Ditiu L, Mchugh TD, Squire SB, Cox H, Ford N, McNerney R, Marais B, Grobusch M, Lawn SD, Migliori GB, Mwaba P, O’Grady J, Pleschette M, Ramsay A, Chakaya, Schito M, Swaminathan S, Mernish Z, Maeurer M, Atun R, Drug-Resistant Tuberculosis—Current Dilemmas, Unanswered Questions, Challenges, and Priority Needs, The Journal Of Infectious Diseases 2012: 205 (supplement 2): S228-240.
Keshavjee S, Farmer P, Tuberculosis, Drug Resistance, and the History of Modern Medicine, The New England Journal of Medicine 2012; 367(10): 931-936.
Current Drug Treatments
Ahuja S, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona J, Becerra M, Benedetti A, Burgos M, Centis R, Chan ED, Chian CY, Cox H, D’Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Ghandi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, C.M. de Lange W, Leimane V, Leung CC, Jiehui L, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O’Riordan, Pai M, Palmero D, Park S, Pasvol G, Pena J, Perez-Guzman C, Quelapio MID, Ponce-de-Leon A, Riekstina V, Robert J, Royce S, Schaaf SH, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Osornio JS, Sotgiu G, Strand MJ, Vargas MH, Viikleep P, Westenhouse J, Wai Yew W, Yim J, Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients, PLoS Medicine 2012; 9(8): e1001300.
Van Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, Daru P, Rieder HL, Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis, American Journal of Respiratory and Critical Care Medicine 2010; 182: 684-692.
Ettehad D, Schaaf SH, Seddon JA, Cooke GS, Ford N, Treatment outcomes for children with multi-drug resistant tuberculosis: a systematic review and meta-analysis, Lancet Infectious Disease 2012; 12: 44.
Future Drug Pipeline
Koul A, Arnoult E, Lounis N, Guillemont J, Andries K, The challenge of new drug discovery for tuberculosis, Nature 2011; 469: 483-490.
Gler MT, Skripconoka V, Epifanio GS, Xiao H, Cabrera-Rivero J, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD, Delamanid for Multidrug-Resistant Pulmonary Tuberculosis 2012; 366(23): 2151-2160.
Woodcock J, Griffin JP, Behrman RE, Development of Novel Combination Therapies, The New England Journal of Medicine 2011; 346(11): 985-987.
Phillips PPJ, Gillespie SH, Boeree M, Heinrich N, Aarnoutse R, McHugh T, Pletschette M, Lienhardt C, Hafner R, Mgone C, Zumla A, Nunn AJ, Hoelshcer M, Innovative Trials Designs Are Practical Solutions for Improving the Treatment of Tuberculosis, The Journal of Infectious Diseases 2012; 205(supplement 2): S250-257.
Lienhardt C, Raviglione M, Spigelman M, Hafner R, Jaramillo E, Hoelscher M, Zumla A, Gheuens, New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promises, and Prospects for the Future, Journal for Infectious Diseases 2012; 205(supplement 2): S241-249.
Clayden P, Collins S, Daniels C, Geffen N, Harrington M, Jeffreys R, Jervis C, Kaplan K, Lessem E, Swan T, HIV i-Base and the Treatment Action Group’s 2012 Pipeline Report
Programmatic
Nackers F, Huerga H, Espie E, Aloo AO, Bastard M, Etard JF, Sitienei J, Varaine F, Chakaya J, Bonnet M, Adherence to Self-Administered Tuberculosis Treatment in a High HIV-Prevalence Setting: A Cross-Sectional Survey in Homa Bay, Kenya, PLoS One 2012; 7(3): e3140.
Nature journal: Chagas Disease supplement. Nature 2010;465(7301 suppl.):S3-S22.
Morris K. After 100 years, time to break silence on Chagas disease [news]. Lancet 2009;9(8):468.
Medecins Sans Frontieres Access Campaign’s Fighting Neglect Report
Diagnostics
Hunter GC, Mayori Katty B, Juarez JA, Neyra RC, Verastegui MR, Malaga Chavez FS, Comejo del Carpio JG, Benzaquen EC, Naquira C, Gilman RH, Bem C, Levy MZ, A Field Trial of Alternative Targeted Screening Strategies for Chagas Disease in Arequipa, Peru, PLoS Neglected Tropical Disease 2012; 6(1): e1468.
Schijman AG, Bisio M, Orellana L, Sued M, Duffy T, Mejia Jaramillo Am, Cura C, Auter F, Veron V, Qvamstrom Y, Deborggraeve S, Hijar G, Zulantay I, Lucero RH, Velazquez E, Tellez T, Sanchez Leon Z, Galvao L, Nolder D, Monje Rumi M, Levi JE< Ramirez JD, Gonzalez P, Acosta Viana K, Yachelini P, Torrico F, Robello C, Assal P, Guhl F, Sosa Estani S, DaSilva A, Britto C, Luquetti A, Ladzins J, International Study to Evaluate PCR Methods for Detection of Trypanosoma cruzi DNA in Blood Samples from Chagas Disease Patients, PLoS Neglected Tropical Diseases 2011: 5(1): e981.
Treatment
Yun O, Lima MA, Ellman T, Chambi W, Castillo S, Flevaud L, Roddy P, Parreno F, Vinas PA, Palma PP, Feasibility, Drug, Safety, and Effectiveness of Etiological Treatment Programs for Chagas Disease in Honduras Guatemala, and Bolivia: 10-Year Experiences of Medecins Sans Frontieres, PLoS Neglected Tropical Diseases 2009; 3(7): e488.
Manne J, Snively CS, Levy MZ, Reich MR, Supply chain problems for Chagas disease treatment, The Lancet 2012; 12: 173-174.
The Lancet. Paediatric Benznidazole [news]. Lancet 2011;378(9809):i.
R&D Pipeline
Ribero I, Sevcsik AM, Alves F, Diap G, Don R, Harhay MO, Chang S, Pecoul B. New, Improved Treatments for Chagas Disease: From the R&D Pipeline to the Patients. PLoS Neglected Tropical Diseases 2009;3(7):e484.
Romanha AJ, Lisboa de Castro S, de Nazare Correia Soeiro M, Lannes-Vieira J, Ribiero I, Talvani A, Bourdini B, Blum B, Olivieri B, Zani C, Spadafora C, Chiari E, Chatelain E, Chaves G, Calzada JE, Bustamante JM, Freitas-Junior LH, Romero LI, Bahia MT, Lotrowska M, Soares M, Andrade SG, Armstrong T, Degrave W, de Araujo Andrade Z, In vitro and in vivo experimental models for drug screening and development for Chagas Disease, Memorias do Instituto Oswaldo Cruz 2010: 105(2): 233-238.
Moon S, Jambert E, Childs M, von Schoen-Angerer T, A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries, Globalization and Health 2011; 7(39). Needle-Free Vaccines
Taberner A, Hogan CN, Hunter IW, Needle-free jet injection using real-time controlled linear Lorentz-force actuators; Medical Engineering & Physics 2012; 34(9): 1228-1235.
Andrianov AK, Mutwiri G, Intradermal immunization using coated microneedles containing an immunoadjuvant; Vaccines 2012: 30: 4355-4360.
Thermostable Vaccines
Lee BY, Cakouros BE, Assi TM, Connor DL, Welling J, Kone S, Djibo A, Wateska A, Pierre L, Brown ST, The impact of making vaccines thermostable in Niger’s vaccine supply, Vaccine 2012; 30: 5637-5643.
Lee BY, Assi TM, Rajgopal J, Norman BA, Chen S, Brown ST, Slayton RB, Kone S, Kenea H, Welling JS, Connor DL, Wateska AR, Jana A, Wiringa AE, Panhuis WGV, Burke DS, Impact of Introducing the Pneumococcal and Rotavirus Vaccines Into the Routine Immunization Program in Niger, American Journal of Public Health 2011; 102(2):269-276.
Stokes-Prindle C, Wanadi C, Aina M, Oni G, Olukowi T, Potel MA, Privor-Dumm L, Levine O, Landscape Analysis of Routine Immunization in Nigeria: Identifying Barriers and Prioritizing Interventions, International Vaccine Access Center 2012.
Ryman TK, Trakroo A, Wallace A, Gupta SK, Wilkins K, Mehta P, Dietz V, Implementation and evaluation of the Reaching Every District (RED) strategy in Assam, India, 2005-2008, Vaccine 2011; 29: 2555-2560.
© 2013 Doctors Without Borders/Médecins Sans Frontières. All rights reserved.
